Estuary Biotherapeutics, Inc.

BiotechnologyBiotechnologyGene TherapyKidney Disease

📍 Menlo Park, CA, USA

StreetZero Signal 81

Be the first to signal interest

About Estuary Biotherapeutics, Inc.

Estuary Biotherapeutics, Inc. is a biotechnology company developing locally administered adeno-associated virus (AAV) gene therapies for autosomal dominant polycystic kidney disease (ADPKD). The therapies target the root genetic causes of the progressive inherited kidney disorder characterized by fluid-filled cysts. The company is a Yale spinout focused on kidney-targeting gene delivery platforms to generate clinical proof-of-concept data for programs EST-201 and EST-101.

LATEST FUNDINGPrivate Placement

$40.7M

Announced 2026-10-16

TOTAL RAISED$103M

🔒

Unlock the full deal profile

Create a free account to see investors, key highlights, news, company details and the AI analysis for Estuary Biotherapeutics, Inc..

Create free account Sign in

Free plan includes 3 full deal profiles every month.

IN THE NEWS

EMPLOYEES—

FOUNDED—

HQMenlo Park, CA, USA

Industry

Biotechnology

Investors

RA Capital Management Deep Track Capital Biogen New Ventures UPMC Enterprises 4BIO Capital GV

Key highlights

Launched with $103M total financing including $93M Series A led by RA Capital Management.
Developing AAV gene therapies EST-201 and EST-101 for ADPKD to reach clinical proof of concept.
Yale spinout leveraging research on reactivating Pkd genes to reverse kidney disease progression.
Backed by investors including Biogen New Ventures, UPMC Enterprises, and the National Kidney Foundation Innovation Fund.